JURA Bio, Inc.

JURA Bio, Inc. is an American biotechnology company based in Boston, Massachusetts, that applies frontier artificial intelligence to therapeutic discovery. The company describes itself as building "foundation models for therapeutic design" — purpose-built AI models trained on proprietary functional data generated by its own wet-lab experiments. Rather than relying on public datasets, JURA operates a closed loop in which its models design molecules, the lab synthesizes and screens them, and the resulting functional signal is fed back to improve the next generation of models. The company frames this as "scaling frontier AI in vitro," arguing that each design–synthesis–screen cycle produces proprietary data at a scale no public dataset can match. JURA's stated deliverables fall into two categories. First, "sovereign AI models": foundation models trained on proprietary functional data for novel modalities and hard targets where public data does not exist and off-the-shelf AI fails. Second, candidate discovery and development: therapeutic candidates with confirmed function, discovered and developed by JURA's AI across modalities including antibodies, TCR mimics, peptides, T-cell engagers, enzymes, and emerging modalities. The company is led by CEO and founder Liz Wood, with Eli Weinstein as Head of Machine Learning Research, Mattia Gollub as CTO, Xiao-Bing Cui and Kerry Dobbs as Co-Heads of R&D, Daniel Hochbaum as Acting CSO, Julio Calzada as Acting CFO, and Elaine Le Lan as Head of Operations. Its scientific advisory board is chaired by George Church, who is also listed as a founder, and includes Lester Mackey, Jay Fishman, and Everett Meyer. Gavin Thurston serves as an advisor for platform translation. Board members include John Ballantyne, Michelle Berg, and Ken LeClair. JURA maintains offices at 100 Morrissey Boulevard in Boston and at Lichtstrasse 35 in Basel, Switzerland, giving it a presence in two major life-science hubs. The company has attracted press attention from outlets including GEN (Genetic Engineering & Biotechnology News), BioInsights, The Conference Forum / IO 360, and DayOne Switzerland, with coverage focused on its AI data loop for de novo antibody design, the removal of DNA synthesis bottlenecks, and its position among notable AI drug discovery companies. JURA is a private company and, as of the available evidence, does not disclose a parent organization or public listing.

JURA Bio, Inc. is an American biotechnology company based in Boston, Massachusetts, focused on applying frontier artificial intelligence to therapeutic discovery. The company emerged from the intersection of machine learning, synthetic biology, and immunology, and its founding team includes CEO Liz Wood and George Church, the prominent geneticist who chairs its scientific advisory board. The company's public positioning centers on a distinctive thesis: that biological AI can achieve "scaling laws" comparable to those seen in language and image models, but only if models are trained on proprietary functional data generated through closed-loop experimentation rather than on public datasets alone. JURA describes its platform as "scaling frontier AI in vitro." Its foundation models are designed to drive wet-lab experiments that generate the data the models need to improve, with each cycle of design, synthesis, and screening producing proprietary functional signal. The company argues that this data is at a scale no public dataset can match, and that it enables work on novel modalities and hard targets where public data does not exist and off-the-shelf AI fails. The company's stated deliverables are twofold: sovereign AI models purpose-built for therapeutic design, and therapeutic candidates with confirmed function across antibodies, TCR mimics, peptides, T-cell engagers, enzymes, and emerging modalities. By late 2024, JURA had begun to attract industry press attention. In November 2024, Genetic Engineering & Biotechnology News named JURA one of six companies worthy of note in AI drug discovery, and DayOne Switzerland covered the company in a piece on balancing innovation and expectations in AI-driven drug discovery. In January 2025, BioInsights published a piece on what removing the DNA synthesis bottleneck means for drug discovery, reflecting JURA's interest in the synthesis and screening infrastructure that underpins its data loop. In July 2025, GEN published coverage of Jura Bio's AI data loop enabling large-scale de novo antibody design, a key validation of the company's closed-loop approach. Further coverage followed in 2026, including a Conference Forum / IO 360 piece on how AI-native drug discovery might change early R&D and a Chinese-language article on scaling laws in biological AI. The company maintains offices at 100 Morrissey Boulevard in Boston and at Lichtstrasse 35 in Basel, Switzerland, positioning it in two major life-science ecosystems. Its leadership team combines drug hunters, machine learning experts, synthetic biologists, immunologists, doctors, patient advocates, and entrepreneurs. JURA is a private company and does not disclose a parent organization or public listing in the available evidence.

• DayOne Switzerland publishes coverage on AI-driven drug discovery and development, featuring JURA.

• GEN names JURA one of six companies worthy of note in AI drug discovery.

• BioInsights publishes a piece on removing the DNA synthesis bottleneck for drug discovery, reflecting JURA's platform interests.

• GEN publishes coverage of Jura Bio's AI data loop enabling large-scale de novo antibody design.

• The Conference Forum / IO 360 publishes a piece on how AI-native drug discovery might change early R&D.

• A Chinese-language article on scaling laws in biological AI and AI drug discovery is published via WeChat.

Frontier AI drug discovery company operating a closed-loop design–synthesis–screen platform that generates proprietary functional data to train sovereign foundation models for hard targets and novel modalities.

• Sovereign AI Models

  Purpose-built foundation models trained on proprietary functional data for novel modalities and hard targets where public data doesn't exist and off-the-shelf AI fails.

• Candidate Discovery & Development

  Therapeutic candidates with confirmed function, discovered and developed by sovereign AI across antibodies, TCR mimics, peptides, T-cell engagers, enzymes, and emerging modalities.

1. 1JURA Bio, Inc. — Official Website Homepagejurabio.com
2. 2Team — JURA Bio, Inc.jurabio.com
3. 3JURA Bio, Inc. — Wikidatawikidata.org